Drugs / Guanfacine Extended Release
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05657860 | Dec 2020 → Dec 2023 | Prader-Willi syndrome, intellectual disability, neurotic excoriation, obesity disorder +1 | Maimonides Medical Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Guanfacine Extended Release | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05657860 ↗ |
| Known as | GXR | “Guanfacine Extended Release (GXR), the investigational drug in this study would be the first study to evaluate the drug in patients with Prader Willi Syndrome.” NCT05657860 ↗ |